Companies: 10,795·Total market cap: $144.5T
GSK plc

GSK plc

GSKNYSEHealthcare● Active
$51.18
$-0.34(-0.66%)
Market Cap$102.9B
P/E Ratio—
52W High$61.7
52W Low$35.45
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

GSK plc (GSK) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001131399 · GSK · NYSE · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
6-K
Latest Form
2026-06-01
Most Recent
1980
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001131399 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-06
Fiscal Year End
Mar 6, 2026
Accession No.
0001131399-26-000004
Primary Document
gsk-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001131399 · Accession 0001131399-26-000004

Latest Key Filings

6-KQuarterly Report
TOTAL VOTING RIGHTS
2026-06-01
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
TOTAL VOTING RIGHTS
2026-06-01
View
6-KCurrent Report (Foreign Issuer)
TRANSACTION IN OWN SHARES
2026-06-01
View
6-KCurrent Report (Foreign Issuer)
POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN
2026-05-28
View
6-KCurrent Report (Foreign Issuer)
DIRECTOR/PDMR SHAREHOLDING
2026-05-27
View
SDSD
SPECIALIZED DISCLOSURE REPORT
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
ADMISSION TO TRADING
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
TRANSACTION IN OWN SHARES
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026
2026-05-22
View
6-KCurrent Report (Foreign Issuer)
DIRECTOR/PDMR SHAREHOLDING
2026-05-20
View
6-KCurrent Report (Foreign Issuer)
DIRECTOR/PDMR SHAREHOLDING
2026-05-20
View
6-KCurrent Report (Foreign Issuer)
DIRECTOR/PDMR SHAREHOLDING
2026-05-19
View
6-KCurrent Report (Foreign Issuer)
TRANSACTION IN OWN SHARES
2026-05-18
View
6-KCurrent Report (Foreign Issuer)
JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR
2026-05-18
View
13F-HR13F-HR
13F-HR
2026-05-14
View
6-KCurrent Report (Foreign Issuer)
DIRECTOR/PDMR SHAREHOLDING
2026-05-14
View
Showing 1–15 of 996 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001131399  |  Exchange: NYSE · Healthcare

GSK plc (NYSE: GSK) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1980. As a Healthcare sector company with CIK 0001131399, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is GSK plc's most comprehensive regulatory disclosure. The most recent GSK plc 10-K was filed on 2026-03-06 for fiscal year ending 2026. Historical GSK 10-K annual reports are available from 2022 through 2026.

Investors researching GSK plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
CVS SEC Filings →BMY SEC Filings →VRTX SEC Filings →SNY SEC Filings →MCK SEC Filings →ELV SEC Filings →HCA SEC Filings →CI SEC Filings →
→ GSK Financials→ GSK Earnings→ GSK Insider Trades

Frequently Asked Questions

GSK SEC Filings · 8 questions

GSK plc (GSK) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. GSK plc's CIK is 0001131399.

GSK SEC filingsGSK plc SEC documentsfind GSK 10-K